US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
about
An overview of international literature from cystic fibrosis registries. Part 5: Update 2012-2015 on lung disease.Nontuberculous mycobacteria in gastrostomy fed patients with cystic fibrosis.Rifabutin Is Active against Mycobacterium abscessus Complex.Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung DiseaseClofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease.Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-resistant Mycobacterium abscessus Lung Disease.The Invisible Army.Highlights from the 2016 North American Cystic Fibrosis Conference.Antibiotic treatment for nontuberculous mycobacterial lung disease.The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease.Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment.Lung transplantation for cystic fibrosis: an update.Impact of pharmacy services on cystic fibrosis medication adherence.Increased survival and proliferation of the epidemic strain Mycobacterium abscessus subsp. massiliense CRM0019 in alveolar epithelial cells.Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the whiB7 Gene.Inhibition of the β-Lactamase BlaMab by Avibactam Improves the In Vitro and In Vivo Efficacy of Imipenem against Mycobacterium abscessus.Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease.Evaluation of a bovine antibody test for diagnosing Mycobacterium avium complex in patients with cystic fibrosis.Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.[Nontuberculous mycobacterial pulmonary disease].Mycobacterium abscessus Complex Infections in Children: A Review.Brazilian guidelines for the diagnosis and treatment of cystic fibrosis.Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectives.First year of the thoracic triumvirate.Establishment and validation of Galleria mellonella as a novel model organism to study Mycobacterium abscessus infection, pathogenesis and treatment.Inhibition of β-lactamases of mycobacteria by avibactam and clavulanate.Nontuberculous Mycobacteria in Cystic Fibrosis.The Clarithromycin Susceptibility Genotype Affects the Treatment Outcome of Patients with Mycobacterium abscessus Lung Disease.Teicoplanin - Tigecycline Combination Shows Synergy Against Mycobacterium abscessus.Osteogenic Sarcoma in an Adolescent With Cystic Fibrosis: Successful Treatment Despite Significant Obstaclesand β-Lactams: Emerging Insights and Potential Opportunities
P2860
Q30244524-CF49EE79-54B7-4AC7-90F9-36C9978A88ACQ33594229-C8AF4151-1981-4848-9FFC-185AC996A323Q33726686-EA412876-1C6F-48DD-A74B-9C60D1D5CE63Q33755342-D289F57C-CD8D-4232-8334-9D58A6617AA1Q37481693-B3D68033-EE76-4CD0-9E11-9AE704374588Q37613058-70964AB0-D1D3-4DCD-9B59-6801899D0DC0Q38404398-F29BA17A-36E2-45E8-9DF7-B289EA897C07Q38663720-5AD3440F-AE6D-4CD1-BD96-1CD3F908BB32Q38665468-ADE6EF7F-EE84-4E20-8928-0EBDFA705977Q38684319-4E6E1C3A-07A0-4386-BBE0-F6881A0325CEQ38770072-767F15C0-79CE-4FAF-AD65-8E7420BF7427Q38853672-27BB7505-921B-4DC3-A05F-A6D1283A92BBQ38871831-8A4809B1-B5B9-48A0-8E0A-41D651C73952Q38969052-CFB95431-967E-4E23-BAEF-3DD650E6CAA4Q39008114-F35632A6-1162-4774-8312-6D14D876EEEAQ39368918-B7091C6D-95CB-4C54-A3CF-DD5466EBD919Q40042910-53B123BF-2A51-4557-AE06-42F5CF0134ABQ40065950-F1BB1689-78AF-4F14-B9D1-A470591A4A0DQ40368667-5AFDF133-0CA5-4AB5-B9DF-B8FABCE091AAQ40397189-61725705-D059-41B7-94DD-43AE846BCC20Q40534009-AE324CDA-F205-4C06-BAFB-B735E3FD6BC5Q40704655-B1236625-555B-4744-B71B-B0A07A5D7C00Q40818353-958E36FA-7DCA-420F-BEE6-E3C08D03432AQ41990551-3516D9E7-14E1-41F3-9E60-F39ABD3BD390Q43538692-F0A2BC41-2BDF-46C5-8948-1139BFACDF53Q47756838-A631DB05-FED4-4165-B3FB-F4CDF0F8627BQ48200012-8A95A0ED-3E0A-4F1B-8D58-31FBC93E6D86Q50044324-82BFEF3F-00D2-4A07-AB94-53CB62102AAEQ51225225-21747180-AE4C-4F5B-9E42-FD556E8232DDQ52768051-A249AB56-8296-442A-A3D5-5093D52ADBC2Q54943989-5B643525-D84A-4895-8FF8-BF249DE29118Q55381713-4257D7F8-9B7F-43B3-97AE-8D5DD22B45E8Q57300050-5BBA1D83-A4F5-4796-90A0-C331B691B50BQ57492057-90B286DF-FB91-4CDA-B212-D446256AC8FF
P2860
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
US Cystic Fibrosis Foundation ...... dividuals with cystic fibrosis
@ast
US Cystic Fibrosis Foundation ...... dividuals with cystic fibrosis
@en
US Cystic Fibrosis Foundation ...... dividuals with cystic fibrosis
@nl
type
label
US Cystic Fibrosis Foundation ...... dividuals with cystic fibrosis
@ast
US Cystic Fibrosis Foundation ...... dividuals with cystic fibrosis
@en
US Cystic Fibrosis Foundation ...... dividuals with cystic fibrosis
@nl
prefLabel
US Cystic Fibrosis Foundation ...... dividuals with cystic fibrosis
@ast
US Cystic Fibrosis Foundation ...... dividuals with cystic fibrosis
@en
US Cystic Fibrosis Foundation ...... dividuals with cystic fibrosis
@nl
P2093
P2860
P50
P1433
P1476
US Cystic Fibrosis Foundation ...... dividuals with cystic fibrosis
@en
P2093
Bruce C Marshall
Charles L Daley
Charles S Haworth
Diana Bilton
Isabelle Sermet-Gaudelus
Jerry A Nick
Karsten Koetz
Kathryn A Sabadosa
Kenneth N Olivier
Kevin L Winthrop
P2860
P356
10.1136/THORAXJNL-2015-207360
P407
P433
P478
71 Suppl 1
P577
2016-01-01T00:00:00Z